Taletrectinib vs placebo after surgery for ROS1-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether taletrectinib (a targeted pill) can help prevent lung cancer from coming back after surgery in people whose tumors have a ROS1 gene change. You would take either taletrectinib or a placebo (inactive pill) for about a year after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer (NSCLC) that is stage IB, II, or IIIA after surgery.
- Your tumor must have a specific change in the ROS1 gene (called a ROS1 rearrangement).
- You must have had surgery to remove all visible cancer, and you must be recovering well (at least 4 weeks after surgery, but no more than 16 weeks if no chemotherapy was given, or up to 30 weeks if you had chemotherapy).
- You cannot have had any prior targeted therapy for your lung cancer, and if you received immunotherapy, it must have been at least 12 weeks ago.
- You must be 18 years or older (or 20 in some countries) and in good overall health (ECOG performance status 0 or 1).
- You cannot have other serious heart, lung, or active infections, and you must not have taken certain medications or foods that affect liver enzymes in the last 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the drug taletrectinib in people with advanced non-small cell lung cancer that has a specific genetic change called ROS1. It is for those who have already tried the drug entrectinib and their cancer progressed. The study aims to see how well taletrectinib works in the real world.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
This study looks at how well a targeted therapy works for people with advanced non-small cell lung cancer that has a specific genetic change called ROS1. It aims to see if this treatment can help control the cancer and improve outcomes.
This trial tests a targeted pill called repotrectinib for people with a specific type of lung cancer (ROS1-positive non-small cell lung cancer) that has spread to the brain. The drug aims to shrink brain tumors and control the cancer, especially when brain-focused treatments like surgery or radiation are not needed right away.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.